AWA
ABBV icon

Arkadios Wealth Advisors’s AbbVie ABBV Stock Holding History

Arkadios Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Sell
65,660
-6,225
-9% -$1.34M 0.25% 85
2026
Q1 		$15.6M Buy
71,885
+3,713
+5% +$824K 0.26% 85
2025
Q4 		$15.6M Buy
68,172
+19,516
+40% +$4.45M 0.3% 60
2025
Q3 		$11.3M Buy
48,656
+6,648
+16% +$1.35M 0.27% 70
2025
Q2 		$7.8M Buy
42,008
+3,963
+10% +$737K 0.23% 96
2025
Q1 		$7.97M Buy
38,045
+4,179
+12% +$812K 0.3% 65
2024
Q4 		$6.02M Sell
33,866
-109
-0.3% -$20K 0.33% 59
2024
Q3 		$6.71M Buy
33,975
+3,334
+11% +$622K 0.38% 54
2024
Q2 		$5.26M Buy
30,641
+3,120
+11% +$517K 0.35% 52
2024
Q1 		$5.01M Sell
27,521
-504
-2% -$86.9K 0.39% 50
2023
Q4 		$4.34M Sell
28,025
-6,295
-18% -$918K 0.37% 56
2023
Q3 		$5.12M Buy
34,320
+9,715
+39% +$1.43M 0.49% 44
2023
Q2 		$3.31M Sell
24,605
-1,720
-7% -$252K 0.39% 61
2023
Q1 		$4.2M Buy
26,325
+1,738
+7% +$266K 0.5% 44
2022
Q4 		$3.97M Buy
24,587
+3,679
+18% +$564K 0.53% 46
2022
Q3 		$2.81M Sell
20,908
-9,535
-31% -$1.37M 0.43% 60
2022
Q2 		$4.66M Buy
30,443
+2,738
+10% +$418K 0.69% 28
2022
Q1 		$4.49M Buy
27,705
+5,142
+23% +$747K 0.59% 37
2021
Q4 		$3.06M Buy
22,563
+2,450
+12% +$289K 0.4% 60
2021
Q3 		$2.17M Buy
20,113
+1,455
+8% +$166K 0.31% 85
2021
Q2 		$2.1M Buy
18,658
+12,343
+195% +$1.39M 0.26% 105
2021
Q1 		$683K Buy
6,315
+764
+14% +$81.7K 0.11% 206
2020
Q4 		$594K Buy
5,551
+3,325
+149% +$320K 0.12% 172
2020
Q3 		$192K Buy
2,226
+489
+28% +$46K 0.1% 184
2020
Q2 		$172K Buy
1,737
+161
+10% +$14.2K 0.1% 170
2020
Q1 		$120K Buy
1,576
+23
+1% +$1.96K 0.08% 212
2019
Q4 		$148K Buy
+1,553
New +$129K 0.09% 184

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arkadios Wealth Advisors's ABBV Position: Q2 2026 in Review

Arkadios Wealth Advisors reduced its AbbVie (ABBV) stake by 8.7% in Q2 2026, selling an estimated $1.34M and leaving 65,660 shares worth $16.5M. The position accounts for 0.25% of the portfolio, ranked #85.

Arkadios Wealth Advisors first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Arkadios Wealth Advisors held 65,660 shares of AbbVie worth $16.5M as of Q2 2026.
  • Arkadios Wealth Advisors sold 6,225 AbbVie shares in Q2 2026, an estimated $1.34M.
  • AbbVie made up 0.25% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #85 holding.
  • Arkadios Wealth Advisors first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.